Competition

Competitors describe Sonova Holding AG's market in their own filings and calls. These verified passages and visual pages show where their strategies meet, using source documents preserved in Sources.

Demant A/S (DEMANT)

Sonova's closest full-line competitor: Demant (Oticon, Bernafon, Philips) goes head-to-head in hearing aids and, through its clinics and the KIND acquisition, in hearing-care retail and diagnostics. Its filings size the shared market and state an explicit ambition to lead hearing healthcare.

Demant states its ambition to become the leader in hearing healthcare and, via the KIND acquisition, its expansion in hearing-aid retail to more than 4,500 clinics globally - the same manufacturer-plus-retail model Sonova runs.

Our strategy is clear: We want to become the leading hearing healthcare company […] We proudly announced and finalised the acquisition of KIND, one of the world’s leading retailers of hearing aids. […] The KIND acquisition makes Demant a leading retailer in Germany and will increase the Group’s revenue by almost 10%. […] Combined with Demant’s existing global clinic footprint, we now have more than 4,500 clinics globally.

p. 7 · Read in context →

Demant's read on the OTC/self-fitting threat and on managed-care pricing pressure: it says over-the-counter hearing aids have had limited impact on the US prescription market so far, but flags newer form factors as a potential risk if they succeed.

The prevalence of large managed care organisations poses a risk to average selling prices in the hearing aid market, as volumes are increasingly consolidated among fewer players. […] Aside from the dynamics of managed care, new channels have emerged in recent years, including over-the-counter hearing aids, which have been publicly available since 2022. While these devices increase general access to treating hearing loss, their impact on the prescription hearing aid market in the US remains limited. Recently, new form factors have also entered the over-the-counter hearing aid market, and while this may increase awareness of hearing loss and expand the penetration of hearing healthcare solutions to new users, it could pose a risk to the prescription hearing aid market, if successful.

p. 38 · Read in context →

Amplifon S.p.A. (AMP)

The global leader in hearing-care retail - the channel where Sonova's own retail arm competes. Amplifon sizes the retail market, claims an ~13% global share, and describes an aggressive store-acquisition and consolidation strategy.

Amplifon's 2025 results and retail M&A: about EUR 2.4bn revenue and ~250 hearing-care centres acquired, plus a network streamlining and the early-2026 divestiture of its UK operations under its 'Fit4Growth' program.

Consolidated revenues for the year reached €2.4 billion, up 1.7% at constant exchange rates […] We continued – especially in the first half of the year – our international expansion, acquiring around 250 hearing care centers across Europe, the United States, and China. […] The program also included a streamlining of the network (with the closure or consolidation of 160 clinics) and a strategic review of the portfolio, which led, in early 2026, to the divesture of our UK operations, allowing greater focus on core, higher potential markets.

p. 8 · Read in context →

Amplifon's stated first strategic pillar - consolidating retail leadership and taking leadership in markets where it is not yet the leader - in the same retail channel where Sonova competes.

The Group aims to strengthen its leadership in all core markets, consolidating its position where it is already a leader and achieving leadership in markets where the Company is not leader yet.

p. 17 · Read in context →

EssilorLuxottica SA (EL)

A large-cap new entrant colliding with Sonova at the low/mild end: EssilorLuxottica's Nuance Audio hearing glasses target mild-to-moderate loss with vision-retail scale, and the company frames traditional hearing aids' visibility, discomfort and price as the adoption barrier it aims to break. Hearing is a small line inside a vision conglomerate.

EssilorLuxottica's Chairman/CEO on its Nuance Audio hearing glasses reaching 15,000 stores across twelve markets - an indication of the distribution reach a vision-retail entrant brings to hearing.

We also launched Nuance Audio hearing-enhancing glasses, now available across 15,000 stores in twelve markets.

p. 5 · Read in context →

EssilorLuxottica's framing of the hearing-solutions market as underpenetrated, attributing the gap partly to the visibility, discomfort and price of traditional hearing aids and citing an 83% WHO service gap - the incumbent model its eyewear device positions against.

Like vision care the hearing solutions market is underpenetrated for a number of reasons, including the visibility of traditional hearing aids, discomfort and price. According to the World Health Organization, globally there is an 83% service gap

p. 26 · Read in context →

Audientes A/S (AUDNTS)

A directional, pure-play read on the value/self-fitting/OTC threat: a micro-cap building affordable, self-fitting hearing aids for underserved and emerging markets - the low-cost end that pressures incumbents like Sonova, though at negligible current scale.

Audientes describes its positioning as a self-fitting, affordable hearing-aid maker aimed at accessibility - a directional view of the value/OTC end of Sonova's market (Audientes is a pre-scale micro-cap).

Audientes A/S is a Danish hearing technology company dedicated to developing smart, self-fitting, and affordable hearing aids and advanced hearables. Our mission is to make high-quality solutions for hearing improvement and enhancement accessible to everyone who needs them globally. […] Ven is a self-fitting, binaural hearing aid designed for individuals with severe to profound hearing loss in one or both ears.

p. 3 · Read in context →

Competition

Demant A/S (DEMANT)

Amplifon S.p.A. (AMP)

EssilorLuxottica SA (EL)

Audientes A/S (AUDNTS)

More peer documents